Anavex Life Sciences Corp Stock OTC Bulletin Board
Equities
AVXL
US0327971026
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
|
07-01 | Anavex Life Sciences Corp.(NasdaqGS:AVXL) added to Russell Small Cap Comp Value Index | CI |
07-01 | Anavex Life Sciences Corp.(NasdaqGS:AVXL) added to Russell 2500 Value Index | CI |
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 493M 674M |
---|---|---|---|---|---|
Net income 2024 * | -43M -58.73M | Net income 2025 * | -56M -76.49M | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-11.2
x | P/E ratio 2025 * |
-9.11
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 96.95% |
Latest transcript on Anavex Life Sciences Corp
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 58 | 13-07-04 | |
Sandra Boenisch
DFI | Director of Finance/CFO | 43 | 15-09-30 |
Edward Hammond
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 58 | 13-07-04 | |
Tom Skarpelos
FOU | Founder | 57 | 04-01-22 |
Jiong Ma
CHM | Chairman | 60 | 21-05-24 |
1st Jan change | Capi. | |
---|---|---|
+20.17% | 126B | |
+24.67% | 118B | |
+23.70% | 27.87B | |
-17.74% | 20.95B | |
-15.73% | 16.92B | |
-15.21% | 16.18B | |
+11.91% | 14.84B | |
-47.10% | 14.79B | |
+54.50% | 14.08B |
- Stock Market
- Equities
- AVXL Stock
- AVXL Stock